Skip to content
DataLookout
Menu

NCT07793513

Study of BK1803 in Healthy Infants

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Start date changed from estimate of Oct 2026 to Oct 21, 2026
    • Secondary endpoints: details revised at 7 of 7 entries
    • Site details revised at 33 of 33 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Antibody seroprotection rates against vaccine antigens in the BK1803 of Main Cohort
Timeframe: 4 weeks from the post-primary immunization of BK1803 in Main Cohort (Visit4)
Antibody seroprotection rates against vaccine antigens for HBs antigen in the Control of Main Cohort
Timeframe: 4 weeks from the post-booster immunization of Bimmugen in Main Cohort (Visit6)
The antibody seroprotection rates against vaccine antigens for PRP, PT and FHA, diphtheria toxin, tetanus toxin, and attenuated poliovirus in the Control of Main Cohort
Timeframe: 4 weeks from the post-primary immunization of GOBIK in Main Cohort (Visit4)

Secondary (7)

Geometric mean antibody titers for HBs antigen
Geometric mean antibody titers for PRP
Geometric mean antibody titers for Bordetella pertussis (PT and FHA)
Geometric mean antibody titers for diphtheria toxin
Geometric mean antibody titers for tetanus toxin
Show 2 moreShow less
Geometric mean antibody titers for attenuated poliovirus
Antibody seroprotection rates against vaccine antigens

Arms and interventions

Safety Lead-in Cohort: BK1803Experimental

Subjects receive BK1803 administered according to the study vaccination schedule, including primary and booster immunizations.

Main Cohort: BK1803Experimental

Subjects receive BK1803 administered according to the study vaccination schedule, including primary and booster immunizations.

Main Cohort: Control (GOBIK and Bimmugen)Active comparator

Subjects receive control vaccines consisting of GOBIK Aqueous Suspension Syringes and Bimmugen® Injection according to the study vaccination schedule, including primary and booster immunizations.

Biologicals: BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection

Sites

33 sites in 1 country